Compare NN & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NN | RLAY |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | 103 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.5B |
| IPO Year | N/A | 2020 |
| Metric | NN | RLAY |
|---|---|---|
| Price | $22.57 | $12.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $25.00 | $19.50 |
| AVG Volume (30 Days) | ★ 3.0M | 2.7M |
| Earning Date | 05-14-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,355,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $324.03 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.44 |
| 52 Week Low | $10.84 | $2.75 |
| 52 Week High | $24.19 | $17.32 |
| Indicator | NN | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 64.63 | 43.17 |
| Support Level | $13.79 | $11.75 |
| Resistance Level | $24.19 | $17.32 |
| Average True Range (ATR) | 1.23 | 0.82 |
| MACD | 0.27 | -0.20 |
| Stochastic Oscillator | 94.71 | 36.54 |
NextNav Inc provides GPS service. The company NextNav TerraPoiNT system delivers resilient, next-generation, complementary positioning, navigation, and timing (PNT) solutions designed to overcome the limitations and vulnerabilities of existing space-based Global Navigation Satellite Systems (GNSS), including the Global Positioning System (GPS). The products of the company include NextNav Pinnacle: Accurate vertical location, NextNav 3D: 3D location visualization, NextNav TerraPoiNT: Resilient PNT for 3D and indoor geolocation, Next Generation Solution: Terrestrial 3D PNT powered by spectrum.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.